Therefore, we proposed that the inhibition of endogenous FA lipogenesis and/or exogenous FAs uptake might be promising to enhance the effect of agents targeting PI3K in breast cancer with resistance to anti-HER2 drugs. The gene discussed is ERBB2; the disease is breast cancer.